Traws Pharma, Inc. has submitted multiple regulatory protocols for its antiviral treatments, including a Phase 2 study for tivoxavir marboxil (TXM) to assess its efficacy against seasonal influenza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results